Research Article: Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang
Abstract:
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in China. Our study aimed to evaluate the screening value of the fatty liver index (FLI), hepatic steatosis index (HSI), lipid accumulation product (LAP), visceral adiposity index (VAI), and Zhejiang University index (ZJU), as well as other single indicators for MAFLD. We aimed to find the optimal screening tool and its appropriate cut-off values for rural Uyghur adults.
Introduction:
In 2020, non-alcoholic fatty liver disease (NAFLD) was renamed metabolic-associated fatty liver disease (MAFLD) [1]. MAFLD is a chronic disease characterized by hepatic fat accumulation and underlying metabolic dysregulation. The condition is a significant public health issue, affecting more than a quarter of adult populations worldwide [2]. Studies have shown that MAFLD induces hepatic lipotoxicity and mitochondrial dysfunction leading to hepatocyte apoptosis, inflammation, and fibrosis [3]. In addition to its…
Read more